Success Metrics

Active Trials

6(86%)

Phase Distribution

Ph phase_3

29%

Ph phase_1

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

5(71.4%)

Phase 3Large-scale testing

2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Detailed Status

Recruiting5

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 15 (71.4%)

Phase 32 (28.6%)

Trials by Status

recruiting571%

active_not_recruiting114%

not_yet_recruiting114%

Recent Activity

6 active trials

Showing 5 of 7

recruitingphase_1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

NCT07140900

recruitingphase_3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674

recruitingphase_1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

NCT07297979

not_yet_recruitingphase_1

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

NCT07493512

recruitingphase_3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07140900Phase 1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Recruiting

NCT07213674Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Recruiting

NCT07297979Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Recruiting

NCT07493512Phase 1

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Not Yet Recruiting

NCT06691984Phase 3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Recruiting

NCT06555796Phase 1

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Active Not Recruiting

NCT06613100Phase 1

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Recruiting

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7